UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Details
Datensatz exportieren als...
BibTeX
mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Cancer research (Chicago, Ill.), 2016-12, Vol.76 (23), p.6911-6923
Driscoll, David R
Karim, Saadia A
Sano, Makoto
Gay, David M
Jacob, Wright
Yu, Jun
Mizukami, Yusuke
Gopinathan, Aarthi
Jodrell, Duncan I
Evans, T R Jeffry
Bardeesy, Nabeel
Hall, Michael N
Quattrochi, Brian J
Klimstra, David S
Barry, Simon T
Sansom, Owen J
Lewis, Brian C
Morton, Jennifer P
2016
Details
Autor(en) / Beteiligte
Driscoll, David R
Karim, Saadia A
Sano, Makoto
Gay, David M
Jacob, Wright
Yu, Jun
Mizukami, Yusuke
Gopinathan, Aarthi
Jodrell, Duncan I
Evans, T R Jeffry
Bardeesy, Nabeel
Hall, Michael N
Quattrochi, Brian J
Klimstra, David S
Barry, Simon T
Sansom, Owen J
Lewis, Brian C
Morton, Jennifer P
Titel
mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Ist Teil von
Cancer research (Chicago, Ill.), 2016-12, Vol.76 (23), p.6911-6923
Ort / Verlag
United States
Erscheinungsjahr
2016
Link zum Volltext
Quelle
EZB Free E-Journals
Beschreibungen/Notizen
mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex. However, clinical trials of mTORC1 inhibitors in pancreatic cancer have failed, raising questions about this therapeutic approach. We employed a genetic approach to delete the obligate mTORC2 subunit Rictor and identified the critical times during which tumorigenesis requires mTORC2 signaling. Rictor deletion resulted in profoundly delayed tumorigenesis. Whereas previous studies showed most pancreatic tumors were insensitive to rapamycin, treatment with a dual mTORC1/2 inhibitor strongly suppressed tumorigenesis. In late-stage tumor-bearing mice, combined mTORC1/2 and PI3K inhibition significantly increased survival. Thus, targeting mTOR may be a potential therapeutic strategy in pancreatic cancer. Cancer Res; 76(23); 6911-23. ©2016 AACR.
Sprache
Englisch
Identifikatoren
ISSN: 0008-5472
eISSN: 1538-7445
DOI: 10.1158/0008-5472.can-16-0810
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5135633
Format
–
Schlagworte
Adenocarcinoma - genetics
,
Adenocarcinoma - pathology
,
Animals
,
Carcinoma, Pancreatic Ductal - genetics
,
Carcinoma, Pancreatic Ductal - pathology
,
Cell Line, Tumor
,
Disease Progression
,
Humans
,
Mice
,
Signal Transduction
,
TOR Serine-Threonine Kinases - genetics
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX